Abstract: . . .  Chair in Cardiovascular Electrophysiology and Professor of Medicine at the University of Montreal and the Montreal Heart Institute, Montreal, Quebec, Canada. PRACTICE POINT Agents that inhibit reninangiotensin signaling are superior to -blockers in hypertensive patients with left-ventricular . . .
. . .  expanding the population of patients who could potentially benefit from AF protection by ARB therapy. The mechanism of benefit, however, is unclear. Atenolol and losartan had similar blood- pressure-lowering capabilities; so anti- hypertensive efficacy is not the issue. Rather, it is more likely that attenuation of angiotensin- . . .
. . .  hypertrophy, and for upstreamtherapy in AF. References 1 Rockson SG and Albers GW (2004) Comparing the guidelines: anticoagulation therapy to optimize stroke prevention in patients with atrial fibrillation . J Am Coll Cardiol 43: 929935 2 Kannel WB et al. (1998) Prevalence, incidence, prognosis, and predisposing . . .
. . .  more likely that attenuation of angiotensin- dependent intracellular signaling is a mediator of ACE-inhibitor and ARB effects. 3 In addition to preventing new-onset AF,losa- rtan also prevented stroke in patients who devel- oped AF. Although this prevention could have been mediated by a reduction in the duration or . . .
. . .  electrical and structural remodeling in atrial fibrillation . J Am Coll Cardiol 41: 21972204 5 Vermes E et al. (2003) Enalapril decreases the incidence of atrial fibrillation in patients with left ventricular dysfunction: insight from the Studies Of Left Ventricular Dysfunction (SOLVD) trials. Circulation 107: 29262931 . . .
. . .  structural remodeling in atrial fibrillation . J Am Coll Cardiol 41: 21972204 5 Vermes E et al. (2003) Enalapril decreases the incidence of atrial fibrillation in patients with left ventricular dysfunction: insight from the Studies Of Left Ventricular Dysfunction (SOLVD) trials. Circulation 107: 29262931  . . .
--2183,6,182,2637,10913